Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BSofiva Genomics 〉Non-Invasive Prenatal Screening+, NIPS+

Non-Invasive Prenatal Screening+, NIPS+

Non-Invasive Prenatal Screening+, NIPS+

By using whole genome NGS and chromosome database from Taiwan and Illumina, Non-invasive prenatal screening+, NIPS+, could examine chromosomal diseases, such as chromosomal aneuploidies and 20 microdeletion syndromes.

Request for Collaboration
SOFIVA Genomics collaborates with illumina®, introduces the patented technique, SAFeR™, which is win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation have started since 2015 to provide pregnant women with excellent international screening services. In Taiwan, NIPS+ is awarded National Biotechnology & Medical Care Quality Award and Symbol of National Quality (SNQ). By combining the conscientious clinical data and the innovative thinking, we build a precise and comprehensive prenatal chromosomal screening with high accuracy.

The outstanding genetic screening technique and the strength of SOFIVA Genomics win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation have started since 2015 to provide pregnant women with excellent international screening services.

By combining the high throughput of next-generation sequencing, bioinformatics analysis of whole genome, and the global chromosomal database, we could perform NIPS+ to detect common chromosomal aneuploidy (Trisomy 21, Trisomy 18, Trisomy 13, and sex chromosome), and analyze 20 selected chromosomal microdeletions with higher accuracy at early stage.
Cooperate with illumina® and introduce the patented technique, SAFeR™, with its clinical database, which was and report will be given in only 8 working days and applied in many medical centers.
With the global database of 500,000 clinical cases, we upgrade the screening and guarantee by choosing and analyzing the 20 chromosomal micro deletions.
It is assured by SNQ (Symbol of National Quality) that the whole process will all be accomplished in Taiwan with high quality and standard, and the screening result can be received in 8 working days only.
It is recommended by society of OB/GYN and has become a trend in the world. The non-invasive procedure won't lead to miscarriage and infection, which is safe without risk.
The earlier you detect, the more relieved you will be. NIPS+ can be applied for pregnant women at 10 weeks of gestation. The detection rate is up to 99.5%*.
*The detection rate of aneuploidy diseases, such as Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), are 99.5%. While the detection rate of 20 chromosomal micro deletions are 90%.
With the complete and detailed reports, physicians examine thoroughly and provide the service of heredity consultation.
Indications of SOFIVA NIPS+
American Congress of Obstetricians and Gynecologists (ACOG) proved the effectiveness of non-invasive prenatal screening in December, 2012. After SOFIVA Genomics and illumina® co-construct a complete database, we even add the analysis of chromosomal microdeletions which provides pregnant women guarantee.
To those pregnant women:
who are ≧ 34-year-old
who worry about the risk of invasive test
who find abnormal ultrasound screening
who have doubt of chromosomal aneuploidies
who have baby born with chromosomal aneuploidies
who have high risk of serum screening of Down Syndrome
who have recurrent pregnancy loss
People who like this also like
  • TBx-Tissue BiopsyTBx-Tissue Biopsy
  • Bendamustine Lyo inj.Bendamustine Lyo inj.
  • GB HBV RealQuant™ PCR KitGB HBV RealQuant™ PCR Kit
  • GADOSCAN®(Gadodiamide)GADOSCAN®(Gadodiamide)
  • Horus DEC 200 Digital hand-held Fundus cameraHorus DEC 200 Digital hand-held Fundus camera
  • Non-Invasive Prenatal Screening, NIPSNon-Invasive Prenatal Screening, NIPS
  • ChlorellaChlorella
  • NaftopidilNaftopidil
  • SB03SB03
  • Zulitor Tablets 4mgZulitor Tablets 4mg